1. Home
  2. VIRT vs ABCL Comparison

VIRT vs ABCL Comparison

Compare VIRT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtu Financial Inc.

VIRT

Virtu Financial Inc.

N/A

Current Price

$53.28

Market Cap

5.0B

Sector

Finance

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

N/A

Current Price

$12.19

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VIRT
ABCL
Founded
2008
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.1B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
VIRT
ABCL
Price
$53.28
$12.19
Analyst Decision
Buy
Strong Buy
Analyst Count
7
12
Target Price
★ $69.43
$16.82
AVG Volume (30 Days)
1.1M
★ 4.3M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 1.77%
N/A
EPS Growth
★ 72.73
10.91
EPS
★ 3.62
N/A
Revenue
★ $3,632,118,000.00
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.12
P/E Ratio
$15.00
★ N/A
Revenue Growth
26.25
★ 160.56
52 Week Low
$31.55
$2.75
52 Week High
$68.76
$14.98

Technical Indicators

Market Signals
Indicator
VIRT
ABCL
Relative Strength Index (RSI) 37.04 48.43
Support Level $51.56 $11.78
Resistance Level $56.48 $12.88
Average True Range (ATR) 1.92 0.83
MACD -0.23 0.01
Stochastic Oscillator 17.59 40.11

Price Performance

Historical Comparison
VIRT
ABCL

About VIRT Virtu Financial Inc.

Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: